Loading…
Loading…
Structured register of government actions in the geoeconomic space — export controls, tariffs, sanctions, FDI screening, subsidies, industrial-policy laws — cross-referenced into the country, minerals, and ETF surface. Charter: docs/IPTM_CHARTER.md.
Severity 1-5 is the qualitative impact rating (1=minor, 5=structural). The bilateral-trade-grounded quant scorer is the next IPTM milestone. RBI (Register Breadth Index) is a complementary structural-breadth indicator from scripts/py/iptm/breadth.py; divergence between RBI and severity is itself informative (high-sev / low-RBI = strategic chokepoint; low-sev / high-RBI = broad but shallow). Every action has at least one primary source URL. Verify-or-don't-file. See also themes, timeline, graph, sankey, map, country exposure, sector exposure, material exposure (+ graph), weekly briefs, portfolio scan, escalation monitor, trans-shipment hubs. Internal triage tools (RSS-poller candidate feed, source-feed health) live under /admin/candidates + /admin/sources. Subscribe via Atom feed (accepts ?country=CN, ?material=lithium, ?issuer=BIS, ?type=export_control, ?etf=SOXX, ?company=NVDA, ?minSeverity=4, ?year=2026, ?q=…) or pull /api/iptm/actions.
The European Commission approved a €400 million German measure in favour of Sanofi-Aventis Deutschland GmbH under EU State aid rules, structured as public service compensation for a service of general economic interest (SGEI) to strengthen the resilience of German/EU insulin supply against production and shortage risk. As its public service obligation, Sanofi must build a new insulin factory at its Industriepark Frankfurt-Höchst site by 31 December 2032 and maintain annual production of at least 1.1 tonnes of insulins there through 31 December 2042.
The UK Office for Life Sciences (OLS) launched the Life Sciences Large Investment Portfolio (LSLIP), a subsidy scheme worth up to GBP 570 million running from implementation in November 2025 to March 2030. The scheme provides direct grants, capped at GBP 130 million per award, to UK-registered private-sector companies committing to invest GBP 250 million or more over three years in domestic manufacturing or commercial R&D across three subsectors: human medicines (APIs and finished products), medical diagnostics, and MedTech. The scheme was referred to the CMA's Subsidy Advice Unit on 21 August 2025, which published its advisory report on 2 October 2025 ahead of the scheme's launch.
On 28 May 2025, Brazilian President Lula launched "Chamada Nordeste" in Salgueiro (Pernambuco) — a BRL 10 billion (~USD 1.8bn) public call for structuring investment projects in the nine Northeast states, run jointly by BNDES, Banco do Brasil, Caixa Econômica Federal, Banco do Nordeste (BNB) and Finep, with technical support from Sudene and the Northeast Consortium. It is the largest project call ever run for the region and sits under the federal Nova Indústria Brasil (NIB) industrial-policy umbrella. Eligible business plans (minimum BRL 10 million) cover storage/renewable energy, bioeconomy with a pharmaceuticals focus, green hydrogen, green data centers and the automotive/agricultural-machinery sector, financed via a combination of credit lines, non-reimbursable economic subsidies and equity participation; the proposal deadline was 15 September 2025. Demand vastly exceeded supply: the call drew 245 proposals totalling roughly BRL 127.8 billion — nearly 13 times the initial BRL 10bn envelope — before BNDES approved 189 projects worth BRL 113 billion in follow-on selection rounds.
The Department of Pharmaceuticals notified the Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs), Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) on 21 July 2020 via Gazette Notification, with an outlay of Rs 6,940 crore (~USD 920m) over FY 2020-21 to FY 2027-28. The scheme covers 41 identified critical bulk-drug products across four target segments — fermentation-based (Key Fermentation; Niche Fermentation) and chemical synthesis-based (Key Chemical Synthesis; Niche Chemical Synthesis) — paying 20% incentive on incremental sales for fermentation-based products (years 1-4) tapering to 15% (year 5) and 5% (year 6), and a flat 20% over 5 years for chemically-synthesised products. The stated objective is to reduce India's ~70% bulk-drug import dependence on China by establishing greenfield domestic manufacturing capacity with at least 90% domestic value addition for fermentation products and 70% for chemical-synthesis products.